Joseph Pantginis Reiterates Buy on $BLRX (BiolineRX) as GLIX1 and CheMo4METPANC Advance and APHEXDA Royalties Support Funding Through 1H 2027

H.C. Wainwright analyst maintained a Buy rating on Bioline RX Ltd Sponsored ADR yesterday and set a price target of $26.00.

Joseph Pantginis has given his Buy rating due to a combination of factors highlighting Bioline RX’s advancing pipeline and upcoming catalysts. He notes that the first-in-class DDR agent GLIX1 is progressing through a Phase 1/2a trial in glioblastoma, with multiple dose-escalation cohorts planned and a Phase 2a expansion design that targets both GBM and additional tumor types, including a future ovarian cancer arm.